For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 21,185 | |||
| General and administrative | 15,956 | |||
| Total operating expenses | 37,141 | |||
| Operating loss | -37,141 | |||
| Impairment charge on investment in equity securities | 0 | |||
| Interest income | 2,377 | |||
| Other expense, net | -6 | |||
| Loss before income taxes | -34,770 | |||
| Income taxes benefit | 0 | |||
| Net loss | -34,770 | |||
| Basic EPS | -4.04 | |||
| Diluted EPS | -4.04 | |||
| Basic Average Shares | 8,611,321 | |||
| Diluted Average Shares | 8,611,321 | |||
ATOSSA THERAPEUTICS, INC. (ATOS)
ATOSSA THERAPEUTICS, INC. (ATOS)